Biofrontera (BFRI) Income towards Parent Company (2020 - 2025)
Biofrontera's (BFRI) quarterly Income towards Parent Company came in at $7.9 million in Q4 2025, up 663.9% year-on-year from $1.0 million in Q4 2024, and up 218.39% quarter-over-quarter from -$6.6 million in Q3 2025.
Biofrontera (BFRI) Income towards Parent Company (2020 - 2025) Analysis & Trends
Biofrontera's Income towards Parent Company history runs 6 years deep, the most recent figure standing at $7.9 million for Q4 2025.
- On a quarterly basis, Income towards Parent Company rose 663.9% year-over-year to $7.9 million in Q4 2025; TTM through Dec 2025 was -$8.3 million, a 53.24% increase from a year earlier, with the FY2025 full-year figure at -$8.3 million, up 53.24% from the prior year.
- Income towards Parent Company climbed to $7.9 million in Q4 2025 per BFRI's latest filing, from -$6.6 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $7.9 million in Q4 2025 and bottomed at -$16.0 million in Q3 2021.
- The 5-year median for Income towards Parent Company is -$3.9 million (2021), against an average of -$4.2 million.
- Across the five-year window, Income towards Parent Company tumbled 7698.39% in 2021 and surged 663.9% in 2025, its largest moves.
- Year by year, Income towards Parent Company stood at -$14.5 million in 2021, then soared by 80.8% to -$2.8 million in 2022, then jumped by 226.61% to $3.5 million in 2023, then plunged by 139.59% to -$1.4 million in 2024, then jumped by 663.9% to $7.9 million in 2025.
- Per Business Quant, the three latest BFRI Income towards Parent Company figures stand at $7.9 million (Q4 2025), -$6.6 million (Q3 2025), and -$5.3 million (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Biofrontera | 10.73 Mn | 4.32 Mn | 14.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 7.87 Mn |
| Sep 30, 2025 | -6.65 Mn |
| Jun 30, 2025 | -5.32 Mn |
| Mar 31, 2025 | -4.20 Mn |
| Dec 31, 2024 | -1.40 Mn |
| Sep 30, 2024 | -5.67 Mn |
| Jun 30, 2024 | -257,000.00 |
| Mar 31, 2024 | -10.44 Mn |
| Dec 31, 2023 | 3.53 Mn |
| Sep 30, 2023 | -6.34 Mn |
| Jun 30, 2023 | -9.84 Mn |
| Mar 31, 2023 | -7.48 Mn |
| Dec 31, 2022 | -2.79 Mn |
| Sep 30, 2022 | -2.57 Mn |
| Jun 30, 2022 | -850,000.00 |
| Mar 31, 2022 | 5.56 Mn |
| Dec 31, 2021 | -14.51 Mn |
| Sep 30, 2021 | -16.01 Mn |
| Jun 30, 2021 | -3.66 Mn |
| Mar 31, 2021 | -3.53 Mn |